A5033597360- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Stress, Anesthesia, and Immune Response
- Tryptophan and brain disorders
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Ethics in Clinical Research
- Bacteriophages and microbial interactions
- Polyomavirus and related diseases
- Urticaria and Related Conditions
- Biomedical Ethics and Regulation
- Lung Cancer Research Studies
- Plant Virus Research Studies
- PARP inhibition in cancer therapy
- Economic and Financial Impacts of Cancer
- Allergic Rhinitis and Sensitization
- Cancer Research and Treatments
- Cardiac electrophysiology and arrhythmias
- Antimicrobial Resistance in Staphylococcus
- Dermatology and Skin Diseases
- Epigenetics and DNA Methylation
Incyte (United States)
2012-2023
Zoetis (United States)
2014
Gundersen Lutheran Hospital
2006
Janus kinase (JAK) enzymes are involved in cell signaling pathways activated by various cytokines dysregulated allergy. The objective of this study was to determine whether the novel JAK inhibitor oclacitinib could reduce activity implicated canine allergic skin disease. Using isolated enzyme systems and vitro human or models, potency selectivity determined against family members that trigger activation cells. Oclacitinib inhibited 50% at concentrations (IC 50 's) ranging from 10 99 n m did...
3010 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that overexpressed in cancers and induces immune tolerance by suppressing T-cell responses. INCB024360, potent, selective IDO1 inhibitor, was generally well tolerated as monotherapy up to 700 mg BID. Preclinical data support anti-tumor synergy for INCB024360 when administered with antibody antagonists checkpoint receptors. Methods: This an ongoing dose-escalation study of combined ipi (3 mg/kg IV q 3...
2500^ Background: The ineffectiveness of the immune system to control tumor growth is, in part, a result immunosuppression imposed by negative regulatory mechanisms. Indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme that catabolizes first and rate-limiting step degradation essential amino acid tryptophan (Trp) kynurenine (Kyn), has been shown preclinically play important role tumor-mediated immunosuppression. In cancer patients (pts), elevated IDO1 levels are associated with poor prognosis...
Abstract Purpose: This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ in combination with pembrolizumab [programmed death-1 (PD-1) inhibitor]. Experimental Design: Patients advanced metastatic solid tumors disease progression following all available therapies were enrolled received (Part initially 300 mg once daily) 10 daily; Part 2...
This was a randomized, four-way crossover study that evaluated the effects of placebo, single doses ruxolitinib 25 and 200 mg, dose moxifloxacin 400 mg on heart rate-corrected QT interval in healthy subjects. Electrocardiograms (ECGs) pharmacokinetic samples were obtained each dosing day; baseline ECGs taken pre-dose. The primary endpoint placebo-subtracted change from (Fridericia formula [ΔΔQTcF]). ΔΔQTcF for either ranged -3.09 to 3.28 milliseconds (1-sided 95% confidence 0.06-6.62...
<div>AbstractPurpose:<p>This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ in combination with pembrolizumab [programmed death-1 (PD-1) inhibitor].</p>Experimental Design:<p>Patients advanced metastatic solid tumors disease progression following all available therapies were enrolled received (Part initially...
<p>Tumor response by RECIST (full analysis set)</p>
INCB099280, an oral programmed death ligand 1 (PD-L1) inhibitor, has shown acceptable safety and preliminary efficacy in advanced solid tumors ongoing phase study (Prenen et al. SITC 2022). As combination treatment (tx) can enhance the antitumor activity of anti-PD-1 therapy, we plan to conduct 2 Phase 1, open label, multicenter studies evaluate INCB099280 tx adults with select tumors. Study 204 will adagrasib, inhibitor KRASG12C, a common mutation non-small cell lung cancer (NSCLC)...
<p>Study design. Note: As of Protocol Amendment 8, enrollment was closed before reaching the planned number patients. <sup>a</sup>Cohort 1 initially evaluated. Cohort −1 evaluated if dose proved intolerable. <sup>b</sup>Cohort Further exploration may be on basis emerging pharmacokinetic/pharmacodynamic or safety data. Subsequent increases in parsaclisib were limited to ≤50% and did not exceed level tested as monotherapy. <sup>c</sup>Patients treated...
<p>IHC analysis of paired screening and on-treatment (week 5–6) tumor biopsies, from patients receiving itacitinib or parsaclisib in combination with pembrolizumab. <b>A,</b> Study Part 1 (T-cell infiltration combined plus intratumoral stromal regions: CD3<sup>+</sup>, CD8<sup>+</sup>, FoxP3<sup>+</sup> cells/mm<sup>2</sup>): (Group A-1 A-2, 300 mg once daily) pembrolizumab 200 every 3 weeks (upper, <i>n</i> = 9);...
<div>AbstractPurpose:<p>This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ in combination with pembrolizumab [programmed death-1 (PD-1) inhibitor].</p>Experimental Design:<p>Patients advanced metastatic solid tumors disease progression following all available therapies were enrolled received (Part initially...
<p>Supplementary Figure 1. Singleplex and Multiplex immunohistochemistry examples.</p>
<p>Summary of itacitinib and parsaclisib treatment-related TEAEs by MedDRA preferred term (≥5% patients in the safety population)</p>